Cyclo Therapeutics- Warrants (14/11/2025) Debt to Equity

The latest debt-to-equity ratio for CYTHW is -0.0. That is below the Healthcare sector average of 0.27. Investors often review this figure alongside Cyclo Therapeutics- Warrants (14/11/2025)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, CYTHW currently prints -0.0 for debt-to-equity ratio, while the sector average sits near 0.27. That is roughly 100.8% below the sector mean. Large gaps often invite a closer look at Cyclo Therapeutics- Warrants (14/11/2025)'s growth, margins, and balance sheet.

A debt-to-equity ratio of -0.0 for Cyclo Therapeutics- Warrants (14/11/2025) is not 'good' or 'bad' on its own. Compare it with the peer average (0.27) and with CYTHW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting CYTHW's debt-to-equity ratio (-0.0), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Cyclo Therapeutics- Warrants (14/11/2025)'s debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.